Cubist Systematic Strategies LLC Buys Shares of 19,903 OrthoPediatrics Corp. (NASDAQ:KIDS)

Cubist Systematic Strategies LLC bought a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,903 shares of the company's stock, valued at approximately $461,000. Cubist Systematic Strategies LLC owned approximately 0.08% of OrthoPediatrics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Northern Trust Corp grew its stake in OrthoPediatrics by 0.3% during the 4th quarter. Northern Trust Corp now owns 193,798 shares of the company's stock valued at $4,492,000 after acquiring an additional 644 shares in the last quarter. Tudor Investment Corp ET AL grew its stake in OrthoPediatrics by 177.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 66,486 shares of the company's stock valued at $1,541,000 after acquiring an additional 42,526 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in OrthoPediatrics by 29.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock valued at $15,576,000 after acquiring an additional 152,681 shares in the last quarter. Wasatch Advisors LP grew its stake in OrthoPediatrics by 47.2% during the 4th quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock valued at $16,141,000 after acquiring an additional 223,217 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of OrthoPediatrics by 12.2% during the 4th quarter. Barclays PLC now owns 28,390 shares of the company's stock valued at $658,000 after buying an additional 3,092 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Stock Up 0.9%

KIDS opened at $23.07 on Friday. The business has a 50 day moving average price of $22.86 and a 200 day moving average price of $23.99. OrthoPediatrics Corp. has a twelve month low of $20.25 and a twelve month high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market cap of $560.30 million, a P/E ratio of -18.76 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The company had revenue of $52.41 million during the quarter, compared to analyst estimates of $51.68 million. Research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus reduced their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a report on Thursday, May 8th. Piper Sandler reduced their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Truist Financial reduced their price target on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 price target for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $35.83.

Insider Buying and Selling

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at $7,934,193.30. The trade was a 2.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is currently owned by insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.